The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index; 13 of the 52 sources its claims cite were checked for support.
Management of Treatment-Resistant Panic Disorder
Open accessAbstract
Purpose of Review: Purpose of Review Management of treatment-resistant (TR) panic disorder (PD) is an unresolved issue. In this paper, we provide a brief summary of previous findings, an updated (2015–2017) systematic review of pharmacological/non-pharmacological studies, and our personal perspective on this topic. Recent Findings: Recent Findings We found a very limited number of recent findings. Quetiapine extended-release augmentation has not been found to be beneficial, in comparison to placebo, in non-responders to previously recommended pharmacotherapy. In non-responders to cognitive behavioral therapy (CBT), switching to paroxetine/citalopram has been found to be more effective than continuing CBT. Acceptance and commitment therapy (ACT) has shown some improvement in patients’ resistance to previous psychological/pharmacological interventions compared with a waiting-list condition. Summary: Summary Previous and recent findings regarding the treatment of TR PD suffer from several methodological limitations. Available studies provide insufficient evidence to support the use of medications alternative to the recommended medications; the efficacy of ACT needs confirmation with more rigorous methodology. Prolonged pharmacotherapy may produce significant improvement in patients with unsatisfactory response to short-term pharmacotherapy, while switching to pharmacotherapy may help non-responders to CBT. We discuss our personal perspective on the definition of “treatment resistance” as it relates to PD and provide personalized intervention strategies to increase favorable clinical outcomes based on our clinical expertise and review of experimental studies on the pathophysiology of PD. © 2017, The Author(s).
Overview
CoChat Summary
## TL;DR
This paper argues that treatment-resistant panic disorder (TRPD) remains poorly defined and poorly studied, and that current evidence is too limited to support alternative medications beyond recommended treatments. Its updated 2015–2017 review found only 3 eligible studies, with mixed results: quetiapine XR did not beat placebo, switching from CBT to SSRIs helped non-responders, and ACT showed some benefit but needs stronger confirmation.
## Key findings
- The authors found a very limited evidence base: from 290 records, only 3 studies met inclusion criteria in the updated review.
- In a small 8-week RCT of adjunctive quetiapine XR vs placebo in SSRI/SNRI-resistant patients with PD, symptoms improved in the whole sample, but there were no significant differences between quetiapine XR and placebo on primary or secondary outcomes.
- In a 3-month randomized controlled trial of patients who did not respond to 12 individual CBT sessions, switching to paroxetine or citalopram led to significantly lower panic symptoms than continuing CBT.
- In a 4-week waiting-list controlled trial, ACT improved panic-phobic symptoms, global illness severity, general anxiety/depressive symptoms, and fear of bodily sensations, but not agoraphobia, anxiety sensitivity, or agoraphobic cognitions.
## Methods
- The paper combined a narrative summary of prior work with an updated systematic review conducted according to PRISMA.
- The search covered PubMed, PsycINFO, and Embase for English-language peer-reviewed studies from January 1, 2015 to July 1, 2017; 290 records were identified and 3 studies were included.
- Included studies had to involve adults (≥18 years) with a primary diagnosis of TRPD, use pharmacological and/or non-pharmacological interventions, and report validated psychometric outcomes; case reports, reviews, editorials, and similar items were excluded.
## Limitations
- The paper states that the evidence suffers from several methodological limitations, including limited sample size, heterogeneous criteria for treatment resistance and outcome measures, and insufficient use of psychometric tools that separately assess panic symptoms, anticipatory anxiety, and phobic avoidance.
- The authors note that the ACT study had a small sample size, no active therapy control, and no information about concomitant medications; the quetiapine XR trial also had a small sample and a mixed/unstandardized definition of SSRI/SNRI resistance.
- Evident from the text: the review included only 3 studies, all within a narrow 2015–2017 window, so the evidence base is very small and may not support broad conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 1 Not valid · 18 Not checked · 13 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results are consistent with other studies that found significant improvement in patients with PD over the course of long-term pharmacotherapy beyond that obtained with short-term treatment with the same medications [39–41].”
§ Management of Treatment-Resistant Panic Disorder > Conclusions > Comments on the available findings
What the sources say
- Not checked — no full text of the sourcecites [39] Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative paroxetine panic study investigators. Acta Psychiatr Scand. 1997;95(2):153–60. source
- Supportedcites [40] Choi KW, Woo JM, Kim YR, et al. Long-term escitalopram treatment in Korean patients with panic disorder: a prospective, naturalistic, open-label, multicenter trial. Clin Psychopharmacol Neurosci. 2012;10(1):44–8. source
The Results (PDSS; page not provided) report significant improvement across weeks 4, 12, and 24 of escitalopram treatment, with response rates rising from 45.4% to 69.7% to 80.7%. The Discussion likewise says improvement continued progressively through week 24, supporting further improvement during longer treatment with the same medication. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [41] Nardi AE, Freire RC, Mochcovitch MD, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012;32(1):120–6. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“in clinical settings, approximately 20–40% of patients did not achieve full remission with the recommended drugs or CBT [10–12]”
§ Management of Treatment-Resistant Panic Disorder > Introduction
What the sources say
- Not checked — no full text of the sourcecites [10] Bandelow B, Ruther E. Treatment-resistant panic disorder. CNS Spectr. 2004;9(10):725–39. source
- Not checked — no full text of the sourcecites [11] Perna G, Guerriero G, Caldirola D. Emerging drugs for panic disorder. Expert Opin Emerg Drugs. 2011;16(4):631–45. source
- Partly supportedcites [12] van Apeldoorn FJ, van Hout WJ, Mersch PP, et al. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand. 2008;117(4):260–70. sourceExperimental — accuracy not yet measured
The Assessment and Treatment effects sections report panic-free and responder outcomes after CBT or SSRI, so the paper supports that not all treated patients reached those outcomes. It does not report a 20–40% failure-to-achieve-full-remission rate. The similar percentages in Attrition (22.9% for SSRI and 39.6% for CBT) are dropout rates, not remission rates; page numbers were unavailable in our copy. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“At the end of the treatment period, the participants who took SSRIs reported significantly lower panic symptoms in comparison to those who continued CBT.”
§ Management of Treatment-Resistant Panic Disorder > The update: a systematic review of pharmacological/non-pharmacological studies in patients with TRPD > Results
What the sources say
- Supportedcites [34] Payne LA, White KS, Gallagher MW, et al. Second-stage treatments for relative nonresponders to cognitive behavioral therapy (cbt) for panic disorder with or without agoraphobia-continued cbt versus ssri: a randomized controlled trial. Depress Anxiety. 2016;33(5):392–9. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“At the end of the treatment period, there was some improvement found in the ACT group in comparison to the WL group in terms of panic-phobic symptoms, global illness severity, general anxiety/depressive symptoms, and fear related to bodily sensations”
§ Management of Treatment-Resistant Panic Disorder > The update: a systematic review of pharmacological/non-pharmacological studies in patients with TRPD > Results
What the sources say
- Supportedcites [35] Gloster AT, Sonntag R, Hoyer J, et al. Treating treatment-resistant patients with panic disorder and agoraphobia using psychotherapy: a randomized controlled switching trial. Psychother Psychosom. 2015;84(2):100–9. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“in a small sample of patients with PD who had not achieved remission after 6 weeks of treatment with sertraline (up to 100 mg/day) or escitalopram (up to 15 mg/day), 6 subsequent weeks of a higher dosage of the same medications (150–200 mg/day or 20–30 mg/day, respectively) did not improve panic/anxiety symptoms in comparison to adjunctive placebo [19].”
§ Management of Treatment-Resistant Panic Disorder > The “state-of-art” in TRPD: previous findings on definition and treatment options
What the sources say
- Supportedcites [19] Simon NM, Otto MW, Worthington JJ, et al. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009;70(11):1563–70. source
The Methods describe six weeks of increased SSRI dose versus continued moderate dose plus placebo for patients not in remission after six weeks. The Discussion reports no evidence of greater benefit from dose increase (Cohen’s d = 0.01), while cautioning that the small Phase 2 sample limits definitive conclusions. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
20 more claims · 1 with their cited sources checked
Create a free account to see all 44 claims and every source verdict.
- It may state two separate claims as one. 15
- The quote only partly states this claim. 1
- Probably not a substantial claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Management of Treatment-Resistant Panic Disorder > Conclusions > Clinical observations
“An open study conducted by our group found that 6 weeks of treatment with citalopram facilitated a significant decrease in balance abnormalities, as measured using posturography, in a sample of patients with PD and agoraphobia [60–64].”
§ Management of Treatment-Resistant Panic Disorder > Conclusions > Clinical observations
“An open study conducted by our group found that 6 weeks of treatment with citalopram facilitated a significant decrease in balance abnormalities, as measured using posturography, in a sample of patients with PD and agoraphobia [65].”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947 · cited 1×
“Introduction Panic disorder (PD) is a chronic, debilitating anxiety disorder that exhibits a lifetime prevalence of 3–4% in the general population [1].”
BackgroundInternational Classification of Diseases, Ninth Revision
National Cancer Institute (2020) · Definitions · doi:10.32388/bd1nux · Cited by 888
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
The International Classification of Diseases: Ninth Revision (ICD-9)
SLEE, V. N. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-3-424 · Cited by 469
Cited by
Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review
Bokma, W. A., Wetzer, G. A. A. M., Gehrels, J. B., Penninx, B. W. J. H., Batelaan, N. M., & Balkom, A. L. J. M. (2019) · Depression and Anxiety · doi:10.1002/da.22895 · Cited by 58
“They consisted of eight narrative reviews (Bakker, Van Balkom, & Stein, 2005; Bandelow et al., 2008; Bystritsky, 2006; Chen & Tsai, 2016; Holt & Lydiard, 2007; Lorenz, Jackson, & Saitz, 2010; Pollack, 2009; Starcevic, 2008), five systematic reviews (Barton et al., 2014; Cosci & Fava, 2013; Ipser et…”
BackgroundFordham, B., Sugavanam, T., Edwards, K., Hemming, K., Howick, J., Copsey, B. J., Lee, H., Kaidesoja, M., Kirtley, S., Hopewell, S., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25090 · Cited by 68
Domschke, K., Seuling, P. D., Schiele, M. A., Bandelow, B., Batelaan, N. M., Bokma, W. A., Branchi, I., Broich, K., Burkauskas, J., Davies, S. J. C., et al. (2024) · World Psychiatry · doi:10.1002/wps.21177 · Cited by 46
“A prerequisite for conducting these clinical trials and mecha nistic studies is an international consensus on the definition of TR AD, which is currently lacking 17,26 .”
Self-citationZhao, C., Wampold, B. E., Ren, Z., Zhang, L., & Guangrong, J. (2022) · Journal of Clinical Psychology · doi:10.1002/jclp.23329 · Cited by 40
Quagliato, L. A., Freire, R. C. R., & Nardi, A. E. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0238-z · Cited by 29
Metadata
- Authors
- Perna, G., & Caldirola, D.
- Affiliations
- Maastricht University (NL)
- Hermanas Hospitalarias del Sagrado Corazón de Jesús (IT)
- Corresponding author
- Perna, Giampaolo
- Venue
- Current Treatment Options in Psychiatry
- Published
- 2017-10-24
- Volume
- 4
- Issue
- 4
- Pages
- 371-386
- ISSN
- 2196-3061 (ISSN-L)
- PMC
- PMC5717132
- OpenAlex
- W2766812746
- Cited by
- 36
- References
- 69
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 8 · 2023: 2 · 2022: 3 · 2021: 8 · 2020: 1 · 2019: 3 · 2018: 5
- FWCI
- 0.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Treatment Options in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Funders
- Maastricht University
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- panic disorder, cognitive behavioral therapy, paroxetine, citalopram, acceptance and commitment therapy, pharmacotherapy, psychological intervention, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Treatment-Resistant Panic Disorder. https://app.cochat.ai/papers/10.1007/s40501-017-0128-7
- The paper
- Perna, G., & Caldirola, D. (2017). Management of Treatment-Resistant Panic Disorder. Current Treatment Options in Psychiatry. https://doi.org/10.1007/s40501-017-0128-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
